Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 15;128(12):2243-2257.
doi: 10.1002/cncr.34170. Epub 2022 Mar 14.

A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer

Affiliations

A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer

Cody M Lebeck Lee et al. Cancer. .

Abstract

The 5-year overall survival rate of a patient with unresectable metastatic colorectal cancer is poor at approximately 14%. Similarly, historical data on liver transplantation (LT) in those with colorectal liver metastases (CRLM) showed poor outcomes, with 5-year survival rates between 12% and 21%. More recently, limited data have shown improved outcomes in select patients with 5-year overall survival rates of approximately 60%. Despite these reported survival improvements, there is no significant improvement in disease-free survival. Given the uncertain benefit with this therapeutic approach and a renewed investigational interest, we aimed to conduct a contemporary systematic review on LT for CRLM. A systematic review of the literature was performed according to the preferred reporting items for systematic reviews and meta-analysis statement. English articles reporting on data regarding LT for CRLM were identified through the MEDLINE (via PubMed), Cochrane Library, and ClinicalTrials.gov databases (last search date: December 16th, 2021) by 2 researchers independently. A total of 58 studies (45 published and 13 ongoing) were included. Although early retrospective studies suggest the possibility that some carefully selected patients may benefit from LT, there is minimal prospective data on the topic and LT remains exploratory in the setting of CRLM. Additionally, several other challenges, such as the limited availability of deceased donor organs and defining appropriate selection criteria, remain when considering the implementation of LT for these patients. Further evidence from ongoing prospective trials is needed to determine if and to what extent there is a role for LT in patients with surgically unresectable CRLM.

Keywords: colorectal neoplasms; liver metastases; liver neoplasms; liver transplantation; unresectable metastatic colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

Rajiv Agarwal received a career development grant from the National Institutes of Health/National Cancer Institute (K12CA090625), honoraria for an American Society of Clinical Oncology (ASCO) Advantage program presentation (April 2021), and personal fees from Ipsen Biopharmaceuticals for the 2020 ASCO Gastrointestinal Cancers Symposium. Daniel B. Brown received research grants from Guerbet and Sirtex Medical. Kristen K. Ciombor reports research funds for Vanderbilt University Medical Center from BMS, Array, Incyte, Daiichi Sankyo, Nucana, AbbVie, Merck, Pfizer, Calithera, and Genentech; consulting fees from Array, Natera, Merck, Pfizer, Lilly/Loxo, Seagen, and Replimune; payments or honoraria for lectures and continuing medical education events from Research to Practice, the PCE Oncology Series, the Mayo Gastrointestinal Symposium, i3Health, OncLive, the MJH Life Sciences ctDNA (circulating tumor DNA [Deoxyribonucleic acid]) series, the LARVOL American Association for Cancer Research abstract discussion, Great Debates in GI Malignancies, the International Society of Gastrointestinal Oncology, Targeted Oncology, and the 2022 ASCO Gastrointestinal Cancers Symposium; flight/accommodation support for an advisory board meeting from Array (November 2019); and an unpaid leadership or fiduciary role with the Academic and Community Cancer Research United board of directors. The other authors made no disclosures.

Figures

Figure 1
Figure 1
Preferred reporting items for systematic reviews and meta‐analysis 2020 flow diagram for new systematic reviews that included searches of databases, registers, and other sources.

References

    1. American Cancer Society Key statistics for colorectal cancer. Accessed July 11, 2021. https://www.cancer.org/cancer/colon‐rectal‐cancer/about/key‐statistics.html
    1. American Society of Clinical Oncology . Colorectal cancer statistics. Accessed December 5, 2021. https://www.cancer.net/cancer‐types/colorectal‐cancer/statistics
    1. American Cancer Society . Colorectal cancer facts and figures. Accessed December 5, 2021. https://www.cancer.org/research/cancer‐facts‐statistics/colorectal‐cance...
    1. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669‐685. doi:10.1001/jama.2021.0106 - DOI - PubMed
    1. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long‐term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125‐135. doi:10.1097/SLA.0b013e31815aa2c2 - DOI - PubMed

Publication types